Effectiveness of IGlarLixi, a Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide, in People with Type 2 Diabetes

INTRODUCTION: The latest Position Statement of the American Diabetes Association/European Association for the Study of Diabetes proposes the use of a fixed-ratio combination (FRC) of a long-acting basal insulin and a glucagon-like peptide-1 receptor agonist as part of treatment intensification. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Kis, János Tibor, Nagy, Gábor, Kovacs, Gábor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385086/
https://www.ncbi.nlm.nih.gov/pubmed/34357560
http://dx.doi.org/10.1007/s13300-021-01128-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385086/
https://www.ncbi.nlm.nih.gov/pubmed/34357560
http://dx.doi.org/10.1007/s13300-021-01128-5

Ejemplares similares